Sean E. George Sells 20,311 Shares of Invitae (NVTA) Stock

Invitae (NYSE:NVTA) CEO Sean E. George sold 20,311 shares of the company’s stock in a transaction that occurred on Tuesday, May 15th. The shares were sold at an average price of $6.96, for a total value of $141,364.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Invitae stock opened at $6.54 on Friday. Invitae has a 12 month low of $5.51 and a 12 month high of $6.45. The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.60 and a current ratio of 2.53.

Invitae (NYSE:NVTA) last posted its earnings results on Wednesday, May 9th. The medical research company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.05). Invitae had a negative net margin of 154.96% and a negative return on equity of 127.38%. The firm had revenue of $27.67 million during the quarter, compared to analyst estimates of $26.86 million. During the same period in the previous year, the company posted ($0.64) EPS. Invitae’s revenue for the quarter was up 167.6% compared to the same quarter last year. sell-side analysts anticipate that Invitae will post -2.22 earnings per share for the current fiscal year.

NVTA has been the topic of several research reports. ValuEngine downgraded Invitae from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Benchmark decreased their target price on Invitae from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, February 13th. JPMorgan Chase decreased their target price on Invitae from $13.00 to $9.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 13th. Finally, Zacks Investment Research raised Invitae from a “hold” rating to a “strong-buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, April 18th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $10.05.

Several institutional investors have recently bought and sold shares of NVTA. Spark Investment Management LLC acquired a new stake in Invitae during the first quarter worth approximately $112,000. Teacher Retirement System of Texas acquired a new stake in Invitae during the fourth quarter worth approximately $116,000. Granite Springs Asset Management LLC acquired a new stake in Invitae during the fourth quarter worth approximately $132,000. MetLife Investment Advisors LLC acquired a new stake in Invitae during the fourth quarter worth approximately $145,000. Finally, Verity Asset Management Inc. grew its position in Invitae by 120.0% during the fourth quarter. Verity Asset Management Inc. now owns 25,186 shares of the medical research company’s stock worth $174,000 after buying an additional 13,740 shares in the last quarter. 71.44% of the stock is currently owned by institutional investors.

Invitae Company Profile

Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders, and other hereditary conditions; proactive health and wellness screening; and preimplantation embryo testing and carrier screening for inherited disorders, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders.

Insider Buying and Selling by Quarter for Invitae (NYSE:NVTA)

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply